Process patent legislation
The House passed Rep. Kastenmeier's (D-Wis.) measure (HR 4899) under suspension of the rules, and the Senate Judiciary Committee passed Sen. Mathias' (R-Md.) legislation (S 1543) unanimously on Sept. 19. Although the Mathias bill is viewed as a compromise between the brandname and generic drug industries, Kastenmeier told the House he "had to reject" its provisions due to the "impact of such proposals on nonpharmaceutical industry process patent holders, workability, and fairness to patent holders." He noted that the Reagan Administration shares his concerns ("The Pink Sheet" Sept. 15, p. 12), but added that he hopes "our differences with the other body can be reconciled before adjournment".
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.